Who are botulinum type a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OnabotulinumtoxinA 100 UNT [Botox], Onabotulinumtoxin A (BoNT), Botulinum neurotoxin (BTX), Botulinum toxin A 50u, Clostridium Botulinum Toxin Type A, Intradetrusor Botox Injections.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-type-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

botulinum type a — Competitive Intelligence Brief

botulinum type a (botulinum type a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; botulinum toxin. Area: Neurology; Dermatology; Aesthetics.

marketed Neurotoxin; botulinum toxin SNARE proteins (synaptobrevin, SNAP-25, syntaxin); acetylcholine release machinery Neurology; Dermatology; Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

botulinum type a (botulinum type a) — Henry Ford Health System. Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
botulinum type a TARGET	botulinum type a	Henry Ford Health System	marketed	Neurotoxin; botulinum toxin	SNARE proteins (synaptobrevin, SNAP-25, syntaxin); acetylcholine release machinery
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A (BoNT)	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum neurotoxin (BTX)	Botulinum neurotoxin (BTX)	The University of Texas Health Science Center, Houston	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (SNAP-25, VAMP, syntaxin)
Botulinum toxin A 50u	Botulinum toxin A 50u	EvergreenHealth	marketed	Neurotoxin; Acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Clostridium Botulinum Toxin Type A	Clostridium Botulinum Toxin Type A	Daewoong Pharmaceutical Co. LTD.	marketed	Neurotoxin; botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; botulinum toxin class)

Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Eisai Co., Ltd. · 1 drug in this class
Henry Ford Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). botulinum type a — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-type-a. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab